BR112016024357A2 - composições de insulina de ação rápida - Google Patents

composições de insulina de ação rápida

Info

Publication number
BR112016024357A2
BR112016024357A2 BR112016024357A BR112016024357A BR112016024357A2 BR 112016024357 A2 BR112016024357 A2 BR 112016024357A2 BR 112016024357 A BR112016024357 A BR 112016024357A BR 112016024357 A BR112016024357 A BR 112016024357A BR 112016024357 A2 BR112016024357 A2 BR 112016024357A2
Authority
BR
Brazil
Prior art keywords
acting insulin
fast acting
insulin compositions
insulin analogue
insulin
Prior art date
Application number
BR112016024357A
Other languages
English (en)
Other versions
BR112016024357B1 (pt
Inventor
Edward CHRISTE Michael
Andrew HARDY Thomas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016024357(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112016024357A2 publication Critical patent/BR112016024357A2/pt
Publication of BR112016024357B1 publication Critical patent/BR112016024357B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se a uma composição de insulina humana ou de análogo de insulina que inclui treprostinil e que tem ação farmacocinética mais rápida do que as formulações comerciais de produtos de análogo de insulina existentes.
BR112016024357-9A 2014-05-08 2015-05-04 Composições farmacêuticas compreendendo uma insulina e treprostinil, seu uso, e artigo de fabricação BR112016024357B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08
US61/990,402 2014-05-08
PCT/US2015/029010 WO2015171484A1 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions

Publications (2)

Publication Number Publication Date
BR112016024357A2 true BR112016024357A2 (pt) 2017-10-10
BR112016024357B1 BR112016024357B1 (pt) 2022-08-23

Family

ID=53189204

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024357-9A BR112016024357B1 (pt) 2014-05-08 2015-05-04 Composições farmacêuticas compreendendo uma insulina e treprostinil, seu uso, e artigo de fabricação

Country Status (36)

Country Link
US (2) US9439952B2 (pt)
EP (3) EP3536380B8 (pt)
JP (1) JP6050902B2 (pt)
KR (1) KR101858890B1 (pt)
CN (1) CN106456717B (pt)
AP (1) AP2016009525A0 (pt)
AR (1) AR100155A1 (pt)
AU (1) AU2015256355B2 (pt)
BR (1) BR112016024357B1 (pt)
CA (1) CA2945188C (pt)
CL (1) CL2016002772A1 (pt)
CY (2) CY1121669T1 (pt)
DK (2) DK3536380T3 (pt)
EA (1) EA031134B1 (pt)
ES (2) ES2733639T3 (pt)
HR (2) HRP20190777T1 (pt)
HU (2) HUE044370T2 (pt)
IL (1) IL248350B (pt)
JO (1) JO3624B1 (pt)
LT (2) LT3140008T (pt)
MA (1) MA39441A1 (pt)
ME (1) ME03384B (pt)
MX (1) MX367521B (pt)
NZ (1) NZ724919A (pt)
PE (1) PE20161408A1 (pt)
PH (1) PH12016502195B1 (pt)
PL (2) PL3536380T3 (pt)
PT (2) PT3140008T (pt)
RS (2) RS58726B1 (pt)
SG (1) SG11201608424WA (pt)
SI (2) SI3536380T1 (pt)
TN (1) TN2016000443A1 (pt)
TR (1) TR201906843T4 (pt)
TW (1) TWI685348B (pt)
UA (1) UA124919C2 (pt)
WO (1) WO2015171484A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
PL2919804T3 (pl) 2012-11-13 2018-07-31 Adocia Szybko działająca formulacja insuliny zawierająca podstawiony związek anionowy
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP2943479B1 (en) 2013-01-11 2020-04-15 Corsair Pharma, Inc. Prodrugs of treprostinil
WO2017015760A1 (en) * 2015-07-28 2017-02-02 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines, S.E.C. A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN114904100A (zh) * 2016-01-29 2022-08-16 曼金德公司 干粉吸入器
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3515430A1 (en) 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
CA3034971A1 (en) 2016-09-29 2018-04-05 Arecor Limited A pharmaceutical insulin formulation
MX2019006463A (es) 2016-12-16 2019-08-14 Novo Nordisk As Composiciones farmaceuticas que contienen insulina.
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
JP6920471B2 (ja) 2017-06-01 2021-08-18 イーライ リリー アンド カンパニー 迅速に作用するインスリン組成物
CA3094237A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277720B2 (en) 2018-04-04 2024-03-01 Arecor Ltd A medical infusion pump system for administration of an insulin compound
US20210093775A1 (en) * 2018-04-04 2021-04-01 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
EA202190552A1 (ru) * 2018-09-18 2021-06-18 Эли Лилли Энд Компани Эрбуминовая соль трепростинила
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
US20220249619A1 (en) * 2019-07-12 2022-08-11 Novo Nordisk A/S High concentration insulin formulation
AU2020337342A1 (en) 2019-08-23 2022-02-24 United Therapeutics Corporation Treprostinil prodrugs
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
CN115916212A (zh) 2020-04-17 2023-04-04 联合治疗公司 曲前列尼尔用于治疗间质性肺病
CN116113415A (zh) 2020-06-09 2023-05-12 联合治疗公司 曲前列尼尔的富马酰基二酮哌啶前药
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途
WO2022132655A1 (en) 2020-12-14 2022-06-23 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) * 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
MXPA04001560A (es) * 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
JP5599543B2 (ja) * 2002-05-07 2014-10-01 ノヴォ ノルディスク アー/エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
KR101186029B1 (ko) * 2004-04-12 2012-09-27 유나이티드 쎄러퓨틱스 코포레이션 신경병증성 당뇨병성 족부 궤양을 치료하기 위한트레프로스티닐의 용도
US20090054473A1 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2010023666A2 (en) 2008-08-28 2010-03-04 Medingo Ltd. Device and method for enhanced subcutaneous insulin absorption
CN102164487A (zh) * 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
PL2340033T3 (pl) 2009-06-26 2014-03-31 Novo Nordisk As Preparat zawierający insulinę, nikotynamid i argininę
US9492422B2 (en) * 2009-11-13 2016-11-15 Toray Industries, Inc. Therapeutic or prophylactic agent for diabetes
KR20140030125A (ko) 2010-12-14 2014-03-11 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
CN103857413A (zh) * 2011-08-12 2014-06-11 阿森迪斯药物股份有限公司 载体连接的曲罗尼尔前药
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
WO2015031709A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations comprising a peptide and a vasodilatory agent
WO2015120457A1 (en) 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Also Published As

Publication number Publication date
KR20160133567A (ko) 2016-11-22
AP2016009525A0 (en) 2016-10-31
HUE044370T2 (hu) 2019-10-28
EP3536380B1 (en) 2021-07-07
WO2015171484A1 (en) 2015-11-12
CY1124454T1 (el) 2022-07-22
CN106456717B (zh) 2020-01-17
JP2016523807A (ja) 2016-08-12
CL2016002772A1 (es) 2017-06-09
AR100155A1 (es) 2016-09-14
PH12016502195A1 (en) 2017-02-06
TWI685348B (zh) 2020-02-21
PT3536380T (pt) 2021-09-02
NZ724919A (en) 2018-01-26
US20160129087A1 (en) 2016-05-12
US9439952B2 (en) 2016-09-13
CA2945188A1 (en) 2015-11-12
EP3140008B1 (en) 2019-04-17
EA201691911A1 (ru) 2017-02-28
IL248350B (en) 2020-03-31
EA031134B1 (ru) 2018-11-30
TR201906843T4 (tr) 2019-05-21
PL3140008T3 (pl) 2019-09-30
US10172922B2 (en) 2019-01-08
MX367521B (es) 2019-08-26
IL248350A0 (en) 2016-11-30
PH12016502195B1 (en) 2017-02-06
ES2733639T3 (es) 2019-12-02
EP3536380B8 (en) 2021-09-22
SI3140008T1 (sl) 2019-06-28
CA2945188C (en) 2018-12-11
SI3536380T1 (sl) 2021-09-30
JO3624B1 (ar) 2020-08-27
CY1121669T1 (el) 2020-07-31
EP3140008A1 (en) 2017-03-15
AU2015256355A1 (en) 2016-10-27
HUE055742T2 (hu) 2021-12-28
CN106456717A (zh) 2017-02-22
LT3140008T (lt) 2019-05-27
EP3536380A1 (en) 2019-09-11
DK3140008T3 (da) 2019-06-24
PE20161408A1 (es) 2016-12-28
EP3943155A1 (en) 2022-01-26
KR101858890B1 (ko) 2018-05-16
ES2891983T3 (es) 2022-02-01
LT3536380T (lt) 2021-08-10
AU2015256355B2 (en) 2017-09-14
US20160367640A1 (en) 2016-12-22
JP6050902B2 (ja) 2016-12-21
HRP20211415T1 (hr) 2021-12-10
RS58726B1 (sr) 2019-06-28
TW201625291A (zh) 2016-07-16
SG11201608424WA (en) 2016-11-29
BR112016024357B1 (pt) 2022-08-23
UA124919C2 (uk) 2021-12-15
PT3140008T (pt) 2019-06-25
HRP20190777T1 (hr) 2019-08-23
TN2016000443A1 (en) 2018-04-04
RS62291B1 (sr) 2021-09-30
MX2016014643A (es) 2017-03-06
PL3536380T3 (pl) 2021-12-27
MA39441A1 (fr) 2017-06-30
ME03384B (me) 2020-01-20
DK3536380T3 (da) 2021-08-02

Similar Documents

Publication Publication Date Title
BR112016024357A2 (pt) composições de insulina de ação rápida
IL289276A (en) Terpanstinil derivatives and preparations containing them and their uses
BR112018001755A2 (pt) composições de insulina de ação rápida
BR112017009277A2 (pt) compostos de silicone
MA39814A (fr) Compositions de parfum
EP3099381A4 (en) Extended release fragrance compositions
EP3221374A4 (en) Moisture curable compositions
PH12017500836A1 (en) Transdermal formulations
BR112016028697A2 (pt) artigos que fornecem fragrâncias de longa duração
EP3149099A4 (en) Synthetic acid compositions and uses thereof
IN2013MU03641A (pt)
MX2017000862A (es) Formulacion de factor viii.
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
IL249695A0 (en) Converted polymyxins and preparations containing them
BR112015022940A2 (pt) composições líquidas de racecadotrila
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
MX2016011401A (es) Composiciones farmaceuticas que comprenden levocetirizina.
EP3177297A4 (en) Compositions relating to vitamin d
BR112017012524A2 (pt) composição contendo éster parcial de carboidrato
BR112016028948A2 (pt) ?composição bifásica?
MX2018005134A (es) Formulacion de factor viii (fviii).
HUP1400082A2 (en) Deodorant composition produced by natural ingredients and process for its preparation
CO2018001431A2 (es) 2,4,7-trimetiloct-6-en-1-ol como ingrediente de fragancia
EP3183330A4 (en) Perfume compositions containing isomeric alkadienals
BR112016028192A2 (pt) gerritdina g. schoonus-gerritsma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2015, OBSERVADAS AS CONDICOES LEGAIS